Leukapheresis in patients newly diagnosed with acute myeloid leukemia.

[1]  H. Bag,et al.  Leukapheresis in acute myeloid leukemia patients with hyperleukocytosis: A single center experience. , 2015, Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis.

[2]  G. Ehninger,et al.  How I treat hyperleukocytosis in acute myeloid leukemia. , 2015, Blood.

[3]  W. Hiddemann,et al.  The Role of Therapeutic Leukapheresis in Hyperleukocytotic AML , 2014, PloS one.

[4]  J. Beyene,et al.  Leukapheresis and low-dose chemotherapy do not reduce early mortality in acute myeloid leukemia hyperleukocytosis: a systematic review and meta-analysis. , 2014, Leukemia research.

[5]  T. Hervig,et al.  Hyperleukocytosis and leukocytapheresis in acute leukaemias: experience from a single centre and review of the literature of leukocytapheresis in acute myeloid leukaemia , 2013, Transfusion medicine.

[6]  Mark E. Williams,et al.  Guidelines on the Use of Therapeutic Apheresis in Clinical Practice—Evidence‐Based Approach from the Writing Committee of the American Society for Apheresis: The Sixth Special Issue , 2013, Journal of clinical apheresis.

[7]  F. Ferrara,et al.  Acute myeloid leukaemia in adults , 2013, The Lancet.

[8]  P. Mintz,et al.  Hyperleukocytosis, leukostasis and leukapheresis: practice management. , 2012, Blood reviews.

[9]  Bob Löwenberg,et al.  Review Articles (434 articles) , 2008 .

[10]  E. Seifried,et al.  Impact of leukapheresis on early death rate in adult acute myeloid leukemia presenting with hyperleukocytosis , 2007, Transfusion.

[11]  P. Porcu,et al.  Therapeutic apheresis in hyperleukocytosis and hyperviscosity syndrome. , 2007, Seminars in thrombosis and hemostasis.

[12]  C. Bloomfield,et al.  Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  C. Bloomfield,et al.  Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461). , 2002, Blood.

[14]  Yu Shen,et al.  Leukapheresis Reduces Early Mortality in Patients with Acute Myeloid Leukemia with High White Cell Counts But Does Not Improve Long Term Survival , 2001, Leukemia & lymphoma.

[15]  M. Slovak,et al.  Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group/Eastern Cooperative Oncology Group study , 2000 .

[16]  X. Thomas,et al.  Impact of pre-induction therapy leukapheresis on treatment outcome in adult acute myelogenous leukemia presenting with hyperleukocytosis , 2000, Annals of Hematology.

[17]  N. Heerema,et al.  Therapeutic leukapheresis in hyperleucocytic leukaemias: lack of correlation between degree of cytoreduction and early mortality rate , 1997, British journal of haematology.